Edition:
United States

Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

6.79USD
25 Apr 2017
Change (% chg)

$0.26 (+3.98%)
Prev Close
$6.53
Open
$6.58
Day's High
$6.88
Day's Low
$6.53
Volume
1,349,771
Avg. Vol
815,727
52-wk High
$11.69
52-wk Low
$5.83

Latest Key Developments (Source: Significant Developments)

Inovio initiates Phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers
Monday, 24 Apr 2017 08:00am EDT 

April 24 (Reuters) - Inovio Pharmaceuticals Inc ::Inovio initiates phase 2 efficacy trial with VGX-3100 for HPV-related vulvar pre-cancers.Plans to initiate a phase 3 study of VGX-3100 as a treatment for high grade cervical dysplasia in 2017.  Full Article

Inovio Ebola vaccine demonstrates robust immune responses with favorable safety profile in expanded clinical trial
Tuesday, 11 Apr 2017 09:00am EDT 

Inovio Pharmaceuticals Inc : Inovio Ebola vaccine demonstrates robust immune responses with favorable safety profile in expanded clinical trial . Inovio Pharma - results across both stages of trial showed that 95 pct of evaluable subjects generated an Ebola-specific antibody immune response . Inovio Pharmaceuticals Inc - Inovio's Ebola vaccine was well-tolerated with a favorable safety profile compared to viral vector-based Ebola vaccines .Inovio Pharmaceuticals Inc - plan to meet with regulators this year regarding a path forward for licensure of Ebola product.  Full Article

Inovio Pharma wins $6.95 mln NIH grant
Thursday, 30 Mar 2017 08:00am EDT 

Inovio Pharmaceuticals Inc : Inovio pharma-co's academic, industry collaborators received multi-year $6.95 million grant from nih's national institute of allergy & infectious diseases .Inovio-Grant to develop single or combination therapy using co's pennvax-gp with goal of attaining long-term hiv remission in absence of antiviral drugs.  Full Article

Inovio's zika vaccine generates robust immune responses in first human study
Wednesday, 21 Dec 2016 08:00am EST 

Inovio Pharmaceuticals Inc : Inovio's zika vaccine generates robust immune responses in first human study .Inovio Pharma- vaccine was well tolerated, no significant safety concerns noted in any of 40 subjects out to 14 weeks from initiation of dosing.  Full Article

Inovio launches Zika vaccine trial
Monday, 29 Aug 2016 07:00am EDT 

Inovio Pharmaceuticals Inc : Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy . Expects to report results before end of this year .Is developing its Zika vaccine, GLS-5700, with Geneone Life Science, Inc. And academic collaborators from US and Canada.  Full Article

Inovio Pharmaceuticals Q2 loss per share $0.26
Monday, 8 Aug 2016 08:00am EDT 

Inovio Pharmaceuticals Inc : Inovio Pharmaceuticals reports 2016 second quarter financial results . Q2 revenue $6.2 million versus $5.3 million . Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.26 .Q2 revenue view $5 million -- Thomson Reuters I/B/E/S.  Full Article

Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial
Tuesday, 26 Jul 2016 10:28am EDT 

Inovio Pharmaceuticals Inc: Inovio Pharmaceuticals doses first subject in Zika vaccine clinical trial . Center phase I trial to evaluate inovio's Zika dna vaccine . Says expect to complete subject dosing and report interim phase I results later this year .Health Canada's Health Products and Food Branch has also approved co's Zika study.  Full Article

Inovio, Geneone Life Science get approval to test Zika vaccine on humans
Monday, 20 Jun 2016 07:00am EDT 

Inovio Pharmaceuticals : Inovio Pharmaceuticals and Geneone Life Science have received approval to initiate a phase i human trial to evaluate it's Zika DNA vaccine .Inovio Pharmaceuticals And Geneone Life Science Receive Approval For First In-Man Zika vaccine clinical trial.  Full Article

Inovio Pharmaceuticals says stock offering of up to $50 mln - SEC Filing
Friday, 17 Jun 2016 05:00pm EDT 

Inovio Pharmaceuticals Inc :May offer and sell shares of common stock having aggregate offering price of up to $50 million through Stifel as sales agent.  Full Article

Inovio Pharmaceuticals reports Q1 loss of $0.11 per share
Monday, 9 May 2016 07:50am EDT 

Inovio Pharmaceuticals Inc : First clinical study of Inovio's zika vaccine is on track to start in 2016 . Inovio Pharmaceuticals reports 2016 first quarter financial results . Q1 loss per share $0.11 . Q1 revenue $8.1 million versus $5.2 million . Q1 revenue view $4.7 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web